Bio-Rad Laboratories, Inc.

NYSE:BIO

Medical - Devices

Healthcare
$370.17 -0.23%

-$0.65 today

Market cap
$9.95B
Beta
1.08
P/E (TTM)
45.4
EPS (TTM)
$6.26
52W Low $228.40High $343.12

Volume 0.46M

Average 0.38M

BIO Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Bio-Rad Laboratories, Inc.NYSE: BIO

Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026

Cost of revenue dips below year-ago levels

Q2 FY2026 cost of revenue of $305.2M fell 0.4% year over year, behind the +3.4% change in trailing-twelve-month cost of revenue. Sequentially, it rose 8.0% from the prior quarter. Over 3 fiscal years it compounded at +0.1% a year.

Context

  • Cost of revenue amounted to 48.0% of revenue in FY2025, up 1.7 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -0.4% toward the trailing-twelve-month pace of +3.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$305.2M+8.0% QoQ
Last fiscal yearDec 2025
$1.24B+4.4% YoY
LTMJun 2026
$1.25B+3.4% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.4%——
1 year+4.4%——
3-year CAGR+0.1%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
1.24B USD
Year-over-year change
+4.4%
4-year CAGR
-0.9%

Cost of Revenue vs competitors

How BIO compares with its peers on the latest reported figures

  • BIO's LTM Jun 2026 cost of revenue of $1.25B is the 5th highest of the 11 companies compared; the peer median is $402.46M.
  • Its year-over-year change of +3.4% is the 6th highest of 11, against a peer median of +3.5%.
  • Cost of revenue amounts to 48.1% of revenue for BIO, versus a peer median of 52.5%.
BIO Competitors Peer median
Cost of Revenue for BIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TMOThermo Fisher Scientific Inc.LTM Sep 2026$27.73B +6.5%+0.5%58.6%
DHRDanaher CorporationLTM Sep 2026$10.6B +12.9%-2.8%41.4%
BRKRBruker CorporationLTM Jun 2026$1.87B +4.7%+14.9%53.3%
RVTYRevvity, Inc.LTM Jul 2026$1.39B +8.5%-4.8%47.9%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$1.25B +3.4%+0.1%48.1%
TECHBio-Techne CorporationLTM Sep 2026$420.61M -0.2%+4.3%34.2%
RGENRepligen CorporationLTM Jun 2026$384.3M +2.3%+4.1%48.9%
AZTAAzenta, Inc.LTM Sep 2026$346.74M +8.6%-7.1%55.8%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$136.53M -10.8%-3.4%65.4%
PACBPacific Biosciences of California, Inc.LTM Mar 2026$100.69M -21.2%+11.3%62.9%
LABStandard BioTools Inc.LTM Mar 2026$44.6M -34.2%-11.1%51.7%
Peer median (excluding BIO) $402.46M+3.5%-1.1%52.5%

Competitors are the stored peer set for BIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.92B2.8B2.67B2.57B2.58B
Cost of Revenue1.28B1.23B1.24B1.19B1.24B
Gross Profit1.64B1.57B1.43B1.38B1.34B
Gross Margin56.1%55.9%53.4%53.7%52.0%
Research & Development260.64M256.89M247.43M295.9M256.9M
Selling, General & Admin877.12M827.83M841.7M814M819.9M
Operating Expenses1.14B1.08B1.09B1.11B1.08B
Depreciation & Amortization137.6M137.3M145.9M151.6M165.4M
EBITDA5.59B(4.53B)(654.8M)(2.14B)1.21B
EBITDA Margin191.2%-161.6%-24.5%-83.5%46.8%
Operating Income500.34M482.62M337.8M269M270.5M
Operating Margin17.1%17.2%12.6%10.5%10.5%
Interest Income18.9M58M100.9M82M95.5M
Interest Expense1.55M38.11M49.44M48.9M49M
Other Income / Expenses4.95B(5.19B)(1.19B)(2.61B)725M
Income Before Tax5.45B(4.7B)(850.1M)(2.34B)995.5M
Pre-Tax Margin186.4%-167.9%-31.8%-91.3%38.5%
Income Tax Expense1.19B(1.08B)(212.78M)(498.3M)235.6M
Net Income4.25B(3.63B)(637.32M)(1.84B)759.9M
Net Margin145.6%-129.5%-23.9%-71.9%29.4%
EPS (Basic)142.61(121.79)(21.82)(65.36)27.87
EPS (Diluted)140.83(121.79)(21.82)(65.36)27.87
Weighted Avg Shares29.83M29.79M29.21M28.21M27.26M
Weighted Avg Shares (Diluted)30.21M29.79M29.21M28.21M27.28M

Bio-Rad Laboratories, Inc.

NYSE:BIO

Intrinsic Alpha fair value

Locked

Current Price

$370.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.